"Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19

COVID-19 Pneumonia Clinical Trial

Official title:

"Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19 Pneumonia Admitted in Intensive Care Unit of a Tertiary Care Hospital in Lahore, Pakistan": A Retrospective Cohort Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05249803
• Other study ID #: FMH-27/12/2021-IRB-983
• Status: Completed
• Start date: March 1, 2021
• Est. completion date: December 31, 2021

Study information

• Verified date: February 2022
• Source: FMH College of Medicine and Dentistry
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

COVID-19, caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is a multisystem disease which primarily involves the respiratory tract. The first case of COVID-19 was identified in late 2019 in the province of Wuhan, China which was followed by the rapid spread of the disease globally, becoming a present-day pandemic.

Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore.

Description:

Objectives: The aim of this study was to describe the clinical characteristics, comorbidities and outcome of the critically sick patients with COVID-19 pneumonia admitted in ICU of a tertiary care hospital in Lahore.

Material & Methods:

Study design: Retrospective study. Study Settings: Study was conducted in Fatima Memorial Hospital, Lahore. Study Duration: Study was conducted on Covid-19 patients who were admitted from March 2021 to August 2021.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 133
• Est. completion date: December 31, 2021
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 85 Years

Eligibility

Inclusion Criteria:

• Critically sick patients with COVID-19 Pneumonia

• All admitted ICU patients with a diagnosis of COVID-19 pneumonia

• Patients having positive reverse transcriptase PCR for COVID-19

• Patients with High-resolution computed tomography (HRCT) chest findings suggestive of COVID-related lung injury

• All patients above 16 years of age with both genders( males and females)

Exclusion Criteria:

• All patients with PCR negative with mild symptoms

• Patients with No signs of COVID-19 pneumonia on HRCT chest

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Pneumonia
• Pneumonia

Intervention

Combination Product:
• Patients with COVID-19 Pneumonia
Patients were offered with usual care of COVID-19 in ICU and we did retrospective study

Locations

Country	Name	City	State
Pakistan	Fatima Memorial Hospital College of Medicine & Dentistry	Lahore	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
FMH College of Medicine and Dentistry

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	The primary endpoint of the study will be to assess the ICU mortality (in percentages% and Numbers) of critically sick patients with COVID-19 pneumonia admitted to the intensive care unit	6 months
Secondary	Comorbidities	we will assess various comorbidities in critically sick patients with COVID-19 pneumonia admitted to the intensive care unit	6 months